The arc of our day at Allicense is to consider the entire biopharma ecosystem – responding to and, when possible, shaping the changing forces that could alter our momentum. How can all industry stakeholders, but especially investors and dealmakers on all sides of the table, work together to prevent a 2011-13-scale choke-off of innovation? What works to preserve our end-game of creating winners all along our value chain, from innovative concept to patients?
Together with 200+ dealmakers, we’ll learn how to make better, more quantifiable deals. To accomplish this mission, Thomson Reuters serves as a catalyst for discussion, learning and innovation. Celebrating its 19th year, this year’s forum will examine the many facets of the evolving relationship among biotech, pharma, VCs, academia and payers.
We are pleased to be joining forces with BIO for the first time in 2016! Allicense’s high-level focus on biopharma dealmaking seemed a perfect fit for the BIO International Convention’s educational mission, networking platform and global reach.
• More than 40% of attendees are SVP level and above
• 200+ Qualified Deal Markers
• Editorially driven program lead by senior Thomson Reuters Recap
• Exclusive opportunity to sponsor event at a range of levels
"An excellent venue for getting updates on the industry and making important contacts and connections. The topics are always relevant and the panels are filled with industry leaders across the spectrum of biotech and pharma.
Intellectually and professionally stimulating, it ranks up there with the top five conferences you’d want to attend."